BioSpace News Archive

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of $12.00 per share for total gross proceeds of $15.3 million, before deducting placement agent fees and offering expenses.

The U.S. Food and Drug Administration today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).

Improved patient outcomes without complicated surgeries create a favorable use case for corneal implant’s application in the cases of presbyopia. The reversible nature of the implant accounts for its popularity amongst the patients as well as medical professionals.

A dozen Boston area anesthesiology residents have launched an eight-week hackathon hosted on GrabCAD.com to design a rapidly deployable, minimum viable mechanical ventilator for patients with COVID-19-related ventilator-dependent lung injury.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced financial results for the full year ended December 31, 2019.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced it has taken multiple steps to focus on the health and welfare of its employees, patients, and customers.

Portola Pharmaceuticals, Inc.® announced that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant to eight new employees of inducement stock options to purchase an aggregate of 16,100 shares of common stock, and awards of 8,050 restricted stock units in the aggregate.

X4 Pharmaceuticals, Inc. announced that on March 31, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Eiger BioPharmaceuticals, Inc. provided an update on the impact of the rapidly progressing global COVID-19 pandemic.

There are dire shortages of personal protective equipment (PPE) in emergency departments across the country, and despite efforts to ramp up production, we do not see significant relief in the near future.